News
AstraZeneca’s Tezspire receives approval for asthma treatment
AstraZeneca’s (AZ) Tezspire has received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca’s (AZ) Tezspire has received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP).